Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
ANVISA issues CGMP to Concord Biotech’s Unit I
Acquisition of exclusive commercialization rights for European markets
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
VeerHealth Care will be raising Rs. 8 crores through bank borrowings
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The restructuring aims to create synergies across the business and strengthen capital structure
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Subscribe To Our Newsletter & Stay Updated
